Search

Your search keyword '"Aoki, Tomokazu"' showing total 166 results
Start Over Author "Aoki, Tomokazu"
166 results on '"Aoki, Tomokazu"'

1. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study

Author

Aoki, Tomokazu, Kagawa, Naoki, Sugiyama, Kazuhiko, Wakabayashi, Toshihiko, Arakawa, Yoshiki, Yamaguchi, Shigeru, Tanaka, Shota, Ishikawa, Eiichi, Muragaki, Yoshihiro, Nagane, Motoo, Nakada, Mitsutoshi, Suehiro, Satoshi, Hata, Nobuhiro, Kuroda, Junichiro, Narita, Yoshitaka, Sonoda, Yukihiko, Iwadate, Yasuo, Natsumeda, Manabu, Nakazato, Yoichi, Minami, Hironobu, Hirata, Yuki, Hagihara, Shunsuke, and Nishikawa, Ryo

Published
2021
Full Text
View/download PDF

4. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

Author

Wakabayashi, Toshihiko, Natsume, Atsushi, Mizusawa, Junki, Katayama, Hiroshi, Fukuda, Haruhiko, Sumi, Minako, Nishikawa, Ryo, Narita, Yoshitaka, Muragaki, Yoshihiro, Maruyama, Takashi, Ito, Tamio, Beppu, Takaaki, Nakamura, Hideo, Kayama, Takamasa, Sato, Shinya, Nagane, Motoo, Mishima, Kazuhiko, Nakasu, Yoko, Kurisu, Kaoru, Yamasaki, Fumiyuki, Sugiyama, Kazuhiko, Onishi, Takanori, Iwadate, Yasuo, Terasaki, Mizuhiko, Kobayashi, Hiroyuki, Matsumura, Akira, Ishikawa, Eiichi, Sasaki, Hikaru, Mukasa, Akitake, Matsuo, Takayuki, Hirano, Hirofumi, Kumabe, Toshihiro, Shinoura, Nobusada, Hashimoto, Naoya, Aoki, Tomokazu, Asai, Akio, Abe, Tatsuya, Yoshino, Atsuo, Arakawa, Yoshiki, Asano, Kenichiro, Yoshimoto, Koji, Shibui, Soichiro, and Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)

Published
2018
Full Text
View/download PDF

5. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study

Author

Nagane, Motoo, primary, Ichimura, Koichi, additional, Onuki, Ritsuko, additional, Narushima, Daichi, additional, Honda-Kitahara, Mai, additional, Satomi, Kaishi, additional, Tomiyama, Arata, additional, Arai, Yasuhito, additional, Shibata, Tatsuhiro, additional, Narita, Yoshitaka, additional, Uzuka, Takeo, additional, Nakamura, Hideo, additional, Nakada, Mitsutoshi, additional, Arakawa, Yoshiki, additional, Ohnishi, Takanori, additional, Mukasa, Akitake, additional, Tanaka, Shota, additional, Wakabayashi, Toshihiko, additional, Aoki, Tomokazu, additional, Aoki, Shigeki, additional, Shibui, Soichiro, additional, Matsutani, Masao, additional, Ishizawa, Keisuke, additional, Yokoo, Hideaki, additional, Suzuki, Hiroyoshi, additional, Morita, Satoshi, additional, Kato, Mamoru, additional, and Nishikawa, Ryo, additional

Published
2022
Full Text
View/download PDF

9. sj-pdf-1-jcb-10.1177_0271678X211063802 - Supplemental material for Predicting cerebral infarction in patients with atrial fibrillation using machine learning: The Fushimi AF registry

Author

Nishi, Hidehisa, Oishi, Naoya, Ogawa, Hisashi, Natsue, Kishida, Doi, Kento, Kawakami, Osamu, Aoki, Tomokazu, Fukuda, Shunichi, Akao, Masaharu, and Tsukahara, Tetsuya

Subjects
110320 Radiology and Organ Imaging, FOS: Clinical medicine, FOS: Biological sciences, Medicine, Cell Biology, 110305 Emergency Medicine, 110306 Endocrinology, Biochemistry, 69999 Biological Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-1-jcb-10.1177_0271678X211063802 for Predicting cerebral infarction in patients with atrial fibrillation using machine learning: The Fushimi AF registry by Hidehisa Nishi, Naoya Oishi, Hisashi Ogawa, Kishida Natsue, Kento Doi, Osamu Kawakami, Tomokazu Aoki, Shunichi Fukuda, Masaharu Akao and Tetsuya Tsukahara in Journal of Cerebral Blood Flow & Metabolism

Published
2021
Full Text
View/download PDF

11. Predicting cerebral infarction in patients with atrial fibrillation using machine learning: The Fushimi AF registry.

Author

Nishi, Hidehisa, Oishi, Naoya, Ogawa, Hisashi, Natsue, Kishida, Doi, Kento, Kawakami, Osamu, Aoki, Tomokazu, Fukuda, Shunichi, Akao, Masaharu, and Tsukahara, Tetsuya

Abstract

The CHADS2 and CHA2DS2-VASc scores are widely used to assess ischemic risk in the patients with atrial fibrillation (AF). However, the discrimination performance of these scores is limited. Using the data from a community-based prospective cohort study, we sought to construct a machine learning-based prediction model for cerebral infarction in patients with AF, and to compare its performance with the existing scores. All consecutive patients with AF treated at 81 study institutions from March 2011 to May 2017 were enrolled (n = 4396). The whole dataset was divided into a derivation cohort (n = 1005) and validation cohort (n = 752) after excluding the patients with valvular AF and anticoagulation therapy. Using the derivation cohort dataset, a machine learning model based on gradient boosting tree algorithm (ML) was built to predict cerebral infarction. In the validation cohort, the receiver operating characteristic area under the curve of the ML model was higher than those of the existing models according to the Hanley and McNeil method: ML, 0.72 (95%CI, 0.66–0.79); CHADS2, 0.61 (95%CI, 0.53–0.69); CHA2DS2-VASc, 0.62 (95%CI, 0.54–0.70). As a conclusion, machine learning algorithm have the potential to perform better than the CHADS2 and CHA2DS2-VASc scores for predicting cerebral infarction in patients with non-valvular AF. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. QOLP-07. HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH BEVACIZUMAB BEYOND PROGRESSION: A PROSPECTIVE TRIAL

Author

Tanaka, Shota, primary, Narita, Yoshitaka, additional, Mukasa, Akitake, additional, Nagane, Motoo, additional, Aoki, Tomokazu, additional, Wakabayashi, Toshihiko, additional, Uzuka, Takeo, additional, Nakamura, Hideo, additional, Arakawa, Yoshiki, additional, Suehiro, Satoshi, additional, Nakada, Mitsutoshi, additional, Morita, Satoshi, additional, Kato, Mamoru, additional, Ichimura, Kouichi, additional, and Nishikawa, Ryo, additional

Published
2020
Full Text
View/download PDF

22. ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS

Author

Ichimura, Koichi, primary, Nagane, Motoo, additional, Kato, Mamoru, additional, Narita, Yoshitaka, additional, Aoki, Tomokazu, additional, Tanaka, Shota, additional, Mukasa, Akitake, additional, Wakabayashi, Toshihiko, additional, Uzuka, Takeo, additional, Nakamura, Hideo, additional, Arakawa, Yoshiki, additional, Suehiro, Satoshi, additional, Nakada, Mitsutoshi, additional, Kitahara, Mai, additional, Hibiya, Yuko, additional, Narushima, Daichi, additional, Onuki, Ritsuko, additional, Morita, Satoshi, additional, and Nishikawa, Ryo, additional

Published
2019
Full Text
View/download PDF

26. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma

Author

Narita, Yoshitaka, primary, Arakawa, Yoshiki, additional, Yamasaki, Fumiyuki, additional, Nishikawa, Ryo, additional, Aoki, Tomokazu, additional, Kanamori, Masayuki, additional, Nagane, Motoo, additional, Kumabe, Toshihiro, additional, Hirose, Yuichi, additional, Ichikawa, Tomotsugu, additional, Kobayashi, Hiroyuki, additional, Fujimaki, Takamitsu, additional, Goto, Hisaharu, additional, Takeshima, Hideo, additional, Ueba, Tetsuya, additional, Abe, Hiroshi, additional, Tamiya, Takashi, additional, Sonoda, Yukihiko, additional, Natsume, Atsushi, additional, Kakuma, Tatsuyuki, additional, Sugita, Yasuo, additional, Komatsu, Nobukazu, additional, Yamada, Akira, additional, Sasada, Tetsuro, additional, Matsueda, Satoko, additional, Shichijo, Shigeki, additional, Itoh, Kyogo, additional, and Terasaki, Mizuhiko, additional

Published
2018
Full Text
View/download PDF

31. A Multicenter Phase I/II Study of the BCNU Implant (Gliadel ® Wafer) for Japanese Patients with Malignant Gliomas

Author

AOKI, Tomokazu, NISHIKAWA, Ryo, SUGIYAMA, Kazuhiko, NONOGUCHI, Naosuke, KAWABATA, Noriyuki, MISHIMA, Kazuhiko, ADACHI, Jun-ichi, KURISU, Kaoru, YAMASAKI, Fumiyuki, TOMINAGA, Teiji, KUMABE, Toshihiro, UEKI, Keisuke, HIGUCHI, Fumi, YAMAMOTO, Tetsuya, ISHIKAWA, Eiichi, TAKESHIMA, Hideo, YAMASHITA, Shinji, ARITA, Kazunori, HIRANO, Hirofumi, YAMADA, Shinobu, and MATSUTANI, Masao

Subjects
Adult, Male, Gastrointestinal Diseases, Polyesters, Kaplan-Meier Estimate, Disease-Free Survival, Japan, Humans, Prospective Studies, pharmacokinetic, Antineoplastic Agents, Alkylating, Aged, Drug Implants, Brain Neoplasms, Neoplasms, Second Primary, Glioma, Middle Aged, Gliadel® Wafer, Carmustine, Combined Modality Therapy, Original Article, Female, Neoplasm Recurrence, Local, Nervous System Diseases, BCNU implant, phase I/II study, Decanoic Acids, malignant gliomas
Abstract

Carmustine (BCNU) implants (Gliadel(®) Wafer, Eisai Inc., New Jersey, USA) for the treatment of malignant gliomas (MGs) were shown to enhance overall survival in comparison to placebo in controlled clinical trials in the United States and Europe. A prospective, multicenter phase I/II study involving Japanese patients with MGs was performed to evaluate the efficacy, safety, and pharmacokinetics of BCNU implants. The study enrolled 16 patients with newly diagnosed MGs and 8 patients with recurrent MGs. After the insertion of BCNU implants (8 sheets maximum, 61.6 mg BCNU) into the removal cavity, various chemotherapies (including temozolomide) and radiotherapies were applied. After placement, overall and progression-free survival rates and whole blood BCNU levels were evaluated. In patients with newly diagnosed MGs, the overall survival rates at 12 months and 24 months were 100.0% and 68.8%, and the progression-free survival rate at 12 months was 62.5%. In patients with recurrent MGs, the progression-free survival rate at 6 months was 37.5%. There were no grade 4 or higher adverse events noted due to BCNU implants, and grade 3 events were observed in 5 of 24 patients (20.8%). Whole blood BCNU levels reached a peak of 19.4 ng/mL approximately 3 hours after insertion, which was lower than 1/600 of the peak BCNU level recorded after intravenous injections. These levels decreased to less than the detection limit (2.00 ng/mL) after 24 hours. The results of this study involving Japanese patients are comparable to those of previous studies in the United States and Europe.

Published
2013

32. Predictors of Cardioembolic Stroke in Japanese Patients with Atrial Fibrillation in the Fushimi AF Registry

Author

Yasuda, Ken, primary, Fukuda, Shunichi, additional, Nakamura, Michikazu, additional, Ohtani, Ryo, additional, Kuwata, Yasuhiro, additional, Takata, Masaki, additional, Sainouchi, Makoto, additional, Gotou, Masahiro, additional, Masuda, Yuichi, additional, Kawarazaki, Satoru, additional, Kawabata, Yasuhiro, additional, Murase, Nagako, additional, Aoki, Tomokazu, additional, Yonemoto, Naohiro, additional, Akao, Masaharu, additional, and Tsukahara, Tetsuya, additional

Published
2018
Full Text
View/download PDF

38. Randomized, double-blind, phase III trial of a personalized peptide vaccination for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy.

Author

Terasaki, Mizuhiko, primary, Narita, Yoshitaka, additional, Arakawa, Yoshiki, additional, Sugiyama, Kazuhiko, additional, Aoki, Tomokazu, additional, Kanamori, Masayuki, additional, Nagane, Motoo, additional, Kumabe, Toshihiro, additional, Hirose, Yuichi, additional, Ichikawa, Tomotsugu, additional, Fujimaki, Takamitsu, additional, Kobayashi, Hiroyuki, additional, Goto, Hisaharu, additional, Takeshima, Hideo, additional, Ueba, Tetsuya, additional, Abe, Hiroshi, additional, Tamiya, Takashi, additional, Sonoda, Yukihiko, additional, Kakuma, Tatsuyuki, additional, and Nishikawa, Ryo, additional

Published
2017
Full Text
View/download PDF

41. randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Author

Narita, Yoshitaka, Arakawa, Yoshiki, Yamasaki, Fumiyuki, Nishikawa, Ryo, Aoki, Tomokazu, Kanamori, Masayuki, Nagane, Motoo, Kumabe, Toshihiro, Hirose, Yuichi, Ichikawa, Tomotsugu, Kobayashi, Hiroyuki, Fujimaki, Takamitsu, Goto, Hisaharu, Takeshima, Hideo, Ueba, Tetsuya, Abe, Hiroshi, Tamiya, Takashi, Sonoda, Yukihiko, Natsume, Atsushi, and Kakuma, Tatsuyuki

Published
2019
Full Text
View/download PDF

43. Successful endovascular treatment of a dissecting aneurysm of vertebral artery associated with double origin of the posterior inferior cerebellar artery.

Author

Kawabata, Yasuhiro, Tsukahara, Tetsuya, Fukuda, Shunichi, Kawarazaki, Satoru, and Aoki, Tomokazu

Subjects
DISSECTING aneurysms, VERTEBRAL artery, BASILAR artery, ANEURYSMS, ARTERIES
Abstract

Background Double origin of the posterior inferior cerebellar artery (DOPICA) has been rarely reported in the literature, with a reported incidence of 1.45%. In contrast, a high concurrence rate of DOPICA and vertebral artery dissecting aneurysm has been reported. Clinical presentation A 61-year old woman presented with vomiting and diplopia with preceding headache. Magnetic resonance imaging (MRI) showed fresh infarction of the left lateral medulla and a vertebral artery dissecting aneurysm of the left vertebral artery. The next day, she exhibited transient loss of consciousness and worsening of headache, and MRI depicted subarachnoid hemorrhage. Four-vessel digital subtraction angiography showed a posterior inferior cerebellar artery (PICA) arising both intracranially and extracranially from the left vertebral artery. Although the dissecting lesion involved the V3 and V4 portion, it did not involve an extracranially originating PICA. Internal trapping of the V3 and V4 portion was chosen as the extracranial channel was expected to supply the PICA territory. This procedure was safely performed. Conclusion Early endovascular intervention should be considered in the treatment of dissecting aneurysm of vertebral artery associated with DOPICA for patients with relatively long lesions even in unruptured cases. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

44. Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme

Author

Terasaki, Mizuhiko, primary, Shibui, Soichiro, additional, Narita, Yoshitaka, additional, Fujimaki, Takamitsu, additional, Aoki, Tomokazu, additional, Kajiwara, Koji, additional, Sawamura, Yutaka, additional, Kurisu, Kaoru, additional, Mineta, Toshihiro, additional, Yamada, Akira, additional, and Itoh, Kyogo, additional

Published
2011
Full Text
View/download PDF

48. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme

Author

Aoki, Tomokazu, primary, Mizutani, Tomohiko, additional, Nojima, Kuniharu, additional, Takagi, Takehisa, additional, Okumura, Ryosuke, additional, Yuba, Yoshiaki, additional, Ueba, Tetsuya, additional, Takahashi, Jun A., additional, Miyatake, Shin-Ichi, additional, Nozaki, Kazuhiko, additional, Taki, Waro, additional, and Matsutani, Masao, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results